104 related articles for article (PubMed ID: 27777246)
1. Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.
Jones BC; Rollison H; Johansson S; Kanebratt KP; Lambert C; Vishwanathan K; Andersson TB
Drug Metab Dispos; 2017 Jan; 45(1):35-41. PubMed ID: 27777246
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.
Zuo R; Li F; Parikh S; Cao L; Cooper KL; Hong Y; Liu J; Faris RA; Li D; Wang H
Drug Metab Dispos; 2017 Feb; 45(2):198-207. PubMed ID: 28062541
[TBL] [Abstract][Full Text] [Related]
3. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of models for predicting drug-drug interactions due to induction.
Fahmi OA; Ripp SL
Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1399-416. PubMed ID: 20955108
[TBL] [Abstract][Full Text] [Related]
6. A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes.
Kamiguchi N; Aoyama E; Okuda T; Moriwaki T
Drug Metab Dispos; 2010 Nov; 38(11):1912-6. PubMed ID: 20699409
[TBL] [Abstract][Full Text] [Related]
7. Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys.
Ohtsuka T; Yoshikawa T; Kozakai K; Tsuneto Y; Uno Y; Utoh M; Yamazaki H; Kume T
Drug Metab Dispos; 2010 Oct; 38(10):1806-13. PubMed ID: 20584745
[TBL] [Abstract][Full Text] [Related]
8. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
[TBL] [Abstract][Full Text] [Related]
9. CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans.
Tippin TK; Hamilton G; Moore L; Beaudet EJ; Jolley S; Brodie TA; Andrews RC; Becherer JD; McDougald DL; Gaul MD; Hoivik DJ; Mellon-Kusibab K; Lehmann J; Kliewer S; Novick S; Laethem R; Zhao Z; LeCluyse EL
Drug Metab Dispos; 2003 Jul; 31(7):870-7. PubMed ID: 12814963
[TBL] [Abstract][Full Text] [Related]
10. Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.
Mao J; Fan P; Wong S; Wang J; Ismaili MHA; Dean B; Hop CECA; Wright M; Chen Y
Pharm Res; 2017 Nov; 34(11):2403-2414. PubMed ID: 28815392
[TBL] [Abstract][Full Text] [Related]
11. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.
LeCluyse EL
Eur J Pharm Sci; 2001 Jul; 13(4):343-68. PubMed ID: 11408150
[TBL] [Abstract][Full Text] [Related]
12. In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells.
Kaneko A; Kato M; Sekiguchi N; Mitsui T; Takeda K; Aso Y
Xenobiotica; 2009 Nov; 39(11):803-10. PubMed ID: 19845431
[TBL] [Abstract][Full Text] [Related]
13. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
[TBL] [Abstract][Full Text] [Related]
14. Cell lines: a tool for in vitro drug metabolism studies.
Donato MT; Lahoz A; Castell JV; Gómez-Lechón MJ
Curr Drug Metab; 2008 Jan; 9(1):1-11. PubMed ID: 18220566
[TBL] [Abstract][Full Text] [Related]
15. Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity.
Aubry AF; Dean B; Diczfalusy U; Goodenough A; Iffland A; McLeod J; Weng N; Yang Z
AAPS J; 2016 Sep; 18(5):1056-1066. PubMed ID: 27350147
[TBL] [Abstract][Full Text] [Related]
16. Measurement of Cytochrome P450 Enzyme Induction and Inhibition in Human Hepatoma Cells.
Rodrigues RM; De Kock J; Doktorova TY; Rogiers V; Vanhaecke T
Methods Mol Biol; 2015; 1250():279-85. PubMed ID: 26272150
[TBL] [Abstract][Full Text] [Related]
17. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical.
Sinz M; Wallace G; Sahi J
AAPS J; 2008 Jun; 10(2):391-400. PubMed ID: 18686044
[TBL] [Abstract][Full Text] [Related]
18. Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships.
Fahmi OA; Raucy JL; Ponce E; Hassanali S; Lasker JM
Drug Metab Dispos; 2012 Nov; 40(11):2204-11. PubMed ID: 22912432
[TBL] [Abstract][Full Text] [Related]
19. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
20. CYP3A induction by liver x receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor.
Shenoy SD; Spencer TA; Mercer-Haines NA; Alipour M; Gargano MD; Runge-Morris M; Kocarek TA
Drug Metab Dispos; 2004 Jan; 32(1):66-71. PubMed ID: 14709622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
